NASDAQ$QURE
uniQure NV · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
uniQure reported financial results for Q1 2024 and highlighted progress across its business.
uniQure made progress on key business priorities in Q1 2024, including advancing AMT-130 for Huntington's disease, initiating new clinical trials, and conserving capital. The company is on track to initiate FDA interactions regarding AMT-130 and provide a clinical update from Phase I/II trials in mid-2024. Enrollment for the Fabry disease study is on track to begin in Q2 2024, with SOD1-ALS and MTLE studies expected to begin in Q3.
- On track to initiate FDA interaction regarding AMT-130 in Q2 2024 and provide a clinical update from the Phase I/II trials in mid-2024.
- Clinical trial initiation for Fabry disease is on track to begin in Q2 2024, followed by refractory mesial temporal lobe epilepsy and SOD1-ALS in Q3 2024.
- A comprehensive review of operations and options to reduce expenses is underway and expected to be completed in mid-2024.
- Cash, cash equivalents and investment securities are expected to fund operations into the second quarter of 2027.
Headline financials
Revenue & EPS history
uniQure · Revenue · Quarterly
$8.49M
Forward guidance
uniQure anticipates several key milestones and activities in the near term, including interactions with the FDA regarding AMT-130, clinical data updates, and the initiation of new clinical trials. The company is also focused on expense reduction and increasing shareholder value.
Tailwinds
- Initiate interactions with the FDA in Q2 2024 to define the clinical and regulatory pathway for AMT-130.
- Provide an update from ongoing Phase I/II clinical trials of AMT-130 in mid-2024, including up to three years of follow-up data on 29 treated patients.
- Complete enrollment in the third cohort of the AMT-130 clinical trial in the second half of 2024.
- Begin patient enrollment in a Phase I/IIa clinical trial for AMT-191 for Fabry disease in Q2 2024.
- Begin patient enrollment in Phase I/II clinical trials for AMT-162 for SOD1 ALS and AMT-260 for refractory MTLE in Q3 2024.
Headwinds
- Clinical results and the development and timing of the Company’s programs
- Company’s interactions with regulatory authorities, which may affect the initiation, timing and progress of clinical trials and pathways to approval
- Company’s ability to continue to build and maintain the company infrastructure and personnel needed to achieve its goals
- Company’s effectiveness in managing current and future clinical trials and regulatory processes
- Impact of global economic uncertainty, rising inflation, rising interest rates or market disruptions on its business.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
+1.0%
Avg return
Earnings day
+2.2%
Avg return
5 days after
+2.6%
Avg return
30 days after
59%
27 / 46 earnings
Positive
+47.1%
Q2 2015
Best reaction
-32.7%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.5% | +34.0% | +35.5% | |
| Q4 2025 | -32.7% | -8.7% | +8.1% | |
| Q3 2025 | -6.0% | +7.5% | -27.5% | |
| Q1 2025 | +3.3% | +17.0% | +15.8% | |
| Q4 2024 | +3.4% | -2.9% | +6.9% | |
| Q3 2024 | +28.8% | +40.1% | +18.5% | |
| Q2 2024 | -4.6% | -1.3% | -23.6% | |
| Q1 2024 | +3.6% | +4.2% | +12.5% | |
| Q4 2023 | -14.8% | -23.6% | -23.0% | |
| Q3 2023 | +6.5% | -0.8% | +19.5% | |
| Q2 2023 | -3.0% | -9.2% | -16.0% | |
| Q1 2023 | +2.7% | +1.2% | -3.8% | |
| Q4 2022 | +5.0% | +6.2% | +1.3% | |
| Q3 2022 | +4.4% | +0.1% | +38.2% | |
| Q2 2022 | -25.5% | -20.2% | -18.4% | |
| Q1 2022 | +6.6% | -2.0% | -5.2% | |
| Q4 2021 | +5.9% | +13.0% | +4.5% | |
| Q3 2021 | -0.3% | +7.1% | +2.2% | |
| Q2 2021 | +8.5% | +11.5% | +10.7% | |
| Q1 2021 | +0.7% | -0.3% | +12.3% | |
| Q4 2020 | -2.0% | -11.5% | -8.2% | |
| Q3 2020 | -10.6% | -7.0% | +7.0% | |
| Q2 2020 | +10.7% | +12.0% | +3.7% | |
| Q1 2020 | +1.0% | -3.2% | +6.6% | |
| Q4 2019 | +1.5% | +1.4% | -11.3% | |
| Q3 2019 | -0.8% | +3.9% | +13.4% | |
| Q2 2019 | -8.5% | -9.1% | -17.1% | |
| Q1 2019 | -2.0% | +2.4% | +5.4% | |
| Q4 2018 | +7.7% | +11.8% | +12.1% | |
| Q3 2018 | +9.0% | +0.5% | +20.1% | |
| Q2 2018 | +6.6% | +9.3% | +21.9% | |
| Q1 2018 | -0.3% | -3.2% | +15.7% | |
| Q4 2017 | -13.5% | -17.2% | +16.9% | |
| Q3 2017 | -2.6% | +4.4% | +4.4% | |
| Q2 2017 | +7.2% | +5.1% | +4.8% | |
| Q1 2017 | +2.3% | +3.3% | +6.6% | |
| Q4 2016 | +1.0% | -3.1% | -10.5% | |
| Q3 2016 | -6.2% | -3.9% | -20.6% | |
| Q1 2016 | +11.8% | +16.8% | -38.5% | |
| Q3 2015 | -12.0% | — | — | |
| Q1 2015 | -2.3% | — | — | |
| Q2 2015 | +47.1% | — | — | |
| Q4 2014 | -7.5% | — | — | |
| Q2 2014 | +10.9% | — | — | |
| Q4 2013 | +3.0% | — | — | |
| Q1 2014 | +0.4% | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro